비오틴 (모발)

Efficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men: randomized, crossover, clinical trial.

1. An Bras Dermatol. 2024 Jul-Aug;99(4):581-584. doi: 10.1016/j.abd.2023.07.008. Epub 2024 Apr 30. Efficacy of 5% topical minoxidil versus 5 mg oral biotin versus topical minoxidil and oral biotin on hair growth in men: randomized, crossover, clinical trial. Valentim FO(1), Miola AC(1), Miot HA

Efficacy of intramuscular injections of biotin and dexpanthenol in the treatment of diffuse hair loss: A randomized, double-blind controlled study comparing two brands.

2. Dermatol Ther. 2022 Sep;35(9):e15695. doi: 10.1111/dth.15695. Epub 2022 Jul 15. Efficacy of intramuscular injections of biotin and dexpanthenol in the treatment of diffuse hair loss: A randomized, double-blind controlled study comparing two brands. Samadi A(1), Ketabi Y(2), Firooz R(1), Firoo

Leupeptin, a calpain inhibitor, protects inner ear hair cells from aminoglycoside ototoxicity.

3. Tohoku J Exp Med. 2006 Jun;209(2):89-97. doi: 10.1620/tjem.209.89. Leupeptin, a calpain inhibitor, protects inner ear hair cells from aminoglycoside ototoxicity. Momiyama J(1), Hashimoto T, Matsubara A, Futai K, Namba A, Shinkawa H. Author information: (1)Department of Otorhinolaryngology, Hi

[Effectiveness of biotin and folic acid supplementation in zinc deficiency].

4. Int J Vitam Nutr Res. 1972;42(4):555-64. [Effectiveness of biotin and folic acid supplementation in zinc deficiency]. [Article in German] Pallauf J, Kirchgessner M. PMID: 4674780 [Indexed for MEDLINE]

Interventions for infantile seborrhoeic dermatitis (including cradle cap).

5. Cochrane Database Syst Rev. 2019 Mar 4;3(3):CD011380. doi: 10.1002/14651858.CD011380.pub2. Interventions for infantile seborrhoeic dermatitis (including cradle cap). Victoire A(1), Magin P, Coughlan J, van Driel ML. Author information: (1)Discipline of General Practice, School of Medicine and

Effects of konjac glucomannan on gastrointestinal symptoms and gut microbiota in athletes with functional constipation: a double-blind randomized controlled trial.

1. Eur J Nutr. 2025 Oct 21;64(8):303. doi: 10.1007/s00394-025-03826-3. Effects of konjac glucomannan on gastrointestinal symptoms and gut microbiota in athletes with functional constipation: a double-blind randomized controlled trial. Zhu Y(1), Chen X(1), Song G(2). Author information: (1)Institute of Sport Science, College of Physical Education, Southwest University, No.2 Tiansheng Road, Beibei District, Chongqing, China. (2)Institute of Sport Science, College of Physical Education, Southwest University, No.2 Tiansheng Road, Beibei District, Chongqing, China. songgang@aliyun.com. PURPOSE: Athletes are at increased risk for functional constipation due to high-intensity training, irregular diets, and disrupted circadian rhythms. Soluble fibers, particularly konjac glucomannan (KGM), have shown potential in alleviating constipation, but clinical evidence, especially in athletes, is limited. This study aimed to assess the effects of an 8-week KGM intervention on gastrointestinal symptoms and gut microbiota in elite male Taekwondo athletes with functional constipation. METHODS: In this double-blind randomized controlled trial, we enrolled male elite Taekwondo athletes diagnosed with functional constipation according to Rome IV criteria. Participants were randomly assigned to receive either KGM supplementation (dietary intervention group, DG) or placebo (control group, CG) for 8 weeks. Primary outcomes included the Patient Assessment of Constipation Symptoms (PAC-SYM), Patient Assessment of Constipation Quality of Life (PAC-QoL), bowel movement frequency (BMF), Bristol Stool Scale, and the Bowel Function Index (BFI). Stool samples were collected for 16S rRNA gene sequencing to evaluate microbial composition and diversity. RESULTS: Compared to the placebo group, the KGM group exhibited significant improvements in PAC-SYM, PAC-QoL, BMF, and BFI scores (p < 0.05 for all). Microbial analysis revealed a marked increase in α-diversity and elevated relative abundances of Prevotella_9, Phascolarctobacterium, Lactobacillus, Bacteroides, and members of the Prevotellaceae family, alongside reduced levels of Alistipes and Desulfovibrio. Correlation analyses indicated a strong association between microbial shifts and symptom improvement. Functional predictions further suggested differential expression in microbial metabolic pathways, including upregulation of biotin biosynthesis I and nitrate reduction VI (assimilatory), and downregulation of L-methionine biosynthesis III (all p < 0.05). CONCLUSIONS: Konjac glucomannan significantly ameliorated gastrointestinal symptoms in elite athletes with functional constipation, potentially via modulation of the gut microbiota. © 2025. Springer-Verlag GmbH Germany, part of Springer Nature. DOI: 10.1007/s00394-025-03826-3 PMID: 41117955 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing Interests: The authors declare no conficts of interest. Ethics approval and consent to participate: This study followed the Helsinki declaration. Participants from the study signed an informed consent form. The study was approved by the Ethics Committee of Southwest University Hospital in Chongqing (No. SHW2023***18).

The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.

2. Cureus. 2025 Jul 31;17(7):e89118. doi: 10.7759/cureus.89118. eCollection 2025 Jul. The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study. Patel MN(1)(2), Maheshvari J(3), Patel N(1). Author information: (1)Clinical Research Operations, NovoBliss Research Private Limited, Ahmedabad, IND. (2)Pharmacology, Swaminarayan University, Ahmedabad, IND. (3)Research and Development, Orgenetics, Inc., Brea, USA. Background Biotin, a vital cofactor for carboxylase enzymes, plays a key role in metabolic processes, while silica is believed to support collagen synthesis, contributing to improved skin and hair health. This study investigates the dermatological benefits of standardized plant-based supplements formulated with biotin derived from Sesbania grandiflora and a biotin-silica blend extracted from Bambusa arundinacea.  Methods A randomized, double-blind, placebo-controlled clinical trial enrolled 105 participants, with 97 completing the 90-day study. Participants received either Treatment A (placebo), Treatment B (botanical extract of standardised for biotin, 1.25 mg orally administered), or Treatment C (botanical extract of standardised for biotin with silica, 1.25 mg biotin with 21.75 mg silica orally administered). Efficacy was evaluated through clinical and instrumental assessments of hair fall and growth rate, skin elasticity, hydration, wrinkle reduction, and nail texture. Results In the post-90-day evaluation, hair fall reduced to 20.61 ± 14.39 (p < 0.001) in biotin and 15.71 ± 10.8 (p < 0.001) in biotin with silica. Hair growth rate increased by 0.55 mm/day (p < 0.0001) in biotin and 0.57 mm/day (p < 0.0001) in biotin with silica. Nail roughness reduced to 0.09 ± 0.29 (p < 0.0001) in biotin and 0.06 ± 0.25 (p < 0.0001) in biotin with silica. Skin elasticity increased to 0.15 ± 0.06 (p < 0.0001) in biotin and 0.17 ± 0.12 (p < 0.0001) in biotin with the silica group. No adverse events were reported.  Conclusion Incorporating Orgen-Bio® and RGen-Si™ into a daily routine may support overall skin, hair, and nail health. The synergistic blend enhances elasticity, reduces wrinkles, boosts hydration, strengthens hair, and improves nail quality-offering effective, long-term cosmetic and structural benefits. Copyright © 2025, Patel et al. DOI: 10.7759/cureus.89118 PMCID: PMC12397994 PMID: 40896024 Conflict of interest statement: Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. ACEAS Independent Ethics Committee issued approval NB230019-OI. The study protocol was approved by the ACEAS - Independent Ethics Committee on June 29, 2023 (approval number: NB230019-OI). The study was registered with Clinical Trials Registry-India (CTRI: CTRI/2023/11/055359) and ClinicalTrials.gov (NCT05972512) for transparency and public access. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: Dr. Jit Maheshvari is employed by Orgenetics, Inc. Financial relationships: Dr. Jit Maheshvari declare(s) employment from Orgenetics, Inc. Nayan Patel declare(s) employment from NovoBliss Research Private Limited. Maheshvari Patel declare(s) employment from NovoBliss Research Private Limited. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Effect of green banana and pineapple fibre powder consumption on host gut microbiome.

3. Front Nutr. 2024 Aug 23;11:1437645. doi: 10.3389/fnut.2024.1437645. eCollection 2024. Effect of green banana and pineapple fibre powder consumption on host gut microbiome. Chong CW(1), Liew MS(2), Ooi W(2), Jamil H(2), Lim A(3), Hooi SL(3), Tay CSC(3), Tan G(3). Author information: (1)School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia. (2)Dole Specialty Ingredients, Dole Asia Holdings Pte., Ltd., Singapore, Singapore. (3)AMILI, Singapore, Singapore. PURPOSE: To determine whether green banana powder (GBP) and pineapple fibre powder (PFP) promote beneficial bacterial species, directly improve human gut health and modulate the gut microbiome and understand their utility as functional foods and dietary supplements. METHODS: Over 14 days, 60 adults followed protocol requirements, completed food diaries and study questionnaires, avoided consuming supplements with prebiotics, probiotics or postbiotics, and ingested food containing 5 g of total daily fibre [placebo (10.75 g), GBP (10.75 g) or PFP (7.41 g)]. Participants' medical and baseline wellness histories, as well as stool samples, were collected at baseline, day 7 and 14. Stool DNA was processed for sequencing. RESULTS: Dietary fibre and resistant starches (RS) in GBP and PFP promoted temporal increases in beneficial bacteria. GBP significantly elevated 7 species (F. prausnitzii, B. longum, B. bifidum, B. adolescentis, B. pseudocatenulatum, B. obeum, and R. inulinivorans), while PFP enriched 6 species (B. ovatus, B. cellulosilyticus, B. bifidum, B. intestinalis, R. inulinivorans, and E. siraeum). These bacteria, found to be deficient in younger adults, were promoted by both powders. PFP benefitted both genders aged 16-23, while GBP benefitted overweight/obese individuals, including females. GBP and PFP fiber and RS improved bowel regularity and health as well as metabolism by promoting histidine, branched-chain amino acids, short-chain fatty acids, and biotin production. The additional fiber caused "low" bloatedness and reduced "fairly bad" sleep disruptions, without affecting sleep durations. CONCLUSION: GBP and PFP supplementation increased beneficial bacteria and metabolites, improved host gut health, and present a valuable nutritional strategy for enhancing human health. CLINICAL TRIAL REGISTRATION: AMILI Institutional Review Board, Identifier 2023/0301. Copyright © 2024 Chong, Liew, Ooi, Jamil, Lim, Hooi, Tay and Tan. DOI: 10.3389/fnut.2024.1437645 PMCID: PMC11378528 PMID: 39246394 Conflict of interest statement: CC consults for AMILI, a private microbiome company, while AL, SH, CT, and GT are employees of AMILI. ML, WO, and HJ are employees of DSI, a B2B business unit under Dole Asia Holdings Pte., Ltd., specializing in the supply of high value natural ingredients for F&B, Nutraceutical and Cosmeceutical Industry.

Case - Biotin supplements interfering with prostate-specific antigen assays A cautionary tale.

4. Can Urol Assoc J. 2024 Nov;18(11):E365-E367. doi: 10.5489/cuaj.8761. Case - Biotin supplements interfering with prostate-specific antigen assays A cautionary tale. Dodbiba L(1), Kavsak PA(2), Hotte SJ(1). Author information: (1)Department of Oncology, McMaster University, Hamilton, ON, Canada. (2)Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. DOI: 10.5489/cuaj.8761 PMCID: PMC11534403 PMID: 38976895 Conflict of interest statement: COMPETING INTERESTS: Dr. Kavsak has participated in advisory boards for laboratory tests related to cardiovascular disease for Quidel, Roche Diagnostics, and Siemens Healthcare Diagnostics; has been a speaker on laboratory tests related to cardiovascular disease for Abbott Diagnostics, Siemens Healthcare Diagnostics, and Thermo Fisher Scientific; has received study grants for laboratory tests related to cardiovascular disease from Abbott Diagnostics, Ortho Clinical Diagnostics, Roche Diagnostics, and Siemens Healthcare Diagnostics; and participated in a clinical trial of female sex specific cutoffs for cardiac troponin (CODE-MI trial) supported by the Canadian Institutes for Health Research. Dr. Hotte has participated in advisory board for AAA-Novartis, Astellas, Bayer, Janssen, and Pfizer; has received grants, grants-in-aid, and honoraria from Astellas, Bayer, BMS, and Janssen; has participated in clinical trials supported by AAA/Novartis, Astellas, BMS, CCTG, Eisai, Merck, Pfizer, SeaGen, and SignalChem (with funds to institution; uncompensated personally); and hold an uncompensated leadership position (Chair, GU Disease Site Group) with the Canadian Cancer Trials Group (CCTG). Dr. Dodbiba does not report any competing personal or financial interests related to this work.

Effect of probiotic administration during pregnancy on the functional diversity of the gut microbiota in healthy pregnant women.

5. Microbiol Spectr. 2024 Jun 4;12(6):e0041324. doi: 10.1128/spectrum.00413-24. Epub 2024 Apr 30. Effect of probiotic administration during pregnancy on the functional diversity of the gut microbiota in healthy pregnant women. Ma G(#)(1), Yan H(#)(1), Tye KD(2), Tang X(1), Luo H(1), Li Z(3), Xiao X(1). Author information: (1)Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China. (2)Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. (3)Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. (#)Contributed equally Our study aims to investigate the impact of probiotic consumption during pregnancy on gut microbiota functional diversity in healthy pregnant women. Thirty-two pregnant women were randomly assigned to two groups. The probiotic group (PG) consisted of pregnant women who consumed triple viable Bifidobacterium longum, Lactobacillus delbrueckii bulgaricus, and Streptococcus thermophilus tablets from the 32nd week of pregnancy until delivery. The functional profiles of the gut microbiota were predicted through high-throughput 16S rRNA sequencing results using PICRUSt software and referencing the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. In the gut microbiota of the PG, the genera Blautia and Ruminococcus, as well as the species Subdoligranulum, showed significantly higher relative abundances compared to the control group (CG) (P < 0.05). At Level 1 of the KEGG signaling pathways, there was a significant reduction in the functional genes of the gut microbiota involved in Organismal Systems in the PG (P < 0.05). In Level 2 of the KEGG signaling pathways, there was a significant reduction in the functional genes of the gut microbiota involved in Infectious Disease in the PG (P < 0.05). In Level 3 of the KEGG signaling pathways, the PG exhibited a significant increase in the functional genes of the gut microbiota involved in ABC transporters, Oxidative phosphorylation, Folate biosynthesis, and Biotin metabolism (P < 0.05). The CG showed a significant increase in the functional genes related to Cysteine and methionine metabolism, Vitamin B6 metabolism, Tuberculosis, and Vibrio cholerae pathogenic cycle (P < 0.05). In conclusion, our findings suggest that probiotic supplementation during pregnancy has a significant impact on functional metabolism in healthy pregnant women. IMPORTANCE: Probiotics are considered beneficial to human health. There is limited understanding of how probiotic consumption during pregnancy affects the functional diversity of the gut microbiota. The aim of our study is to investigate the impact of probiotic consumption during pregnancy on the functional diversity of the gut microbiota. Our findings suggest that probiotic supplementation during pregnancy has a significant impact on functional metabolism. This could potentially open up new avenues for preventing various pregnancy-related complications. This also provides new insights into the effects of probiotic consumption during pregnancy on the gut microbiota and offers a convenient method for exploring the potential mechanisms underlying the impact of probiotics on the gut microbiota of pregnant women. DOI: 10.1128/spectrum.00413-24 PMCID: PMC11237737 PMID: 38687069 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.

Efficacy and Safety of Skin Radiance Collagen on Skin and Hair Matrix: A Placebo-Controlled Clinical Trial in Healthy Human Subjects.

6. Clin Cosmet Investig Dermatol. 2024 Mar 11;17:581-591. doi: 10.2147/CCID.S438642. eCollection 2024. Efficacy and Safety of Skin Radiance Collagen on Skin and Hair Matrix: A Placebo-Controlled Clinical Trial in Healthy Human Subjects. Trehan A(1), Anand R(1), Chaudhary G(1), Garg H(1), Verma MK(1). Author information: (1)Bright Lifecare Pvt. Ltd, Gurugram, Haryana, India. PURPOSE: Collagen supplements are rising in the market as collagen has been demonstrated to be an important protein in the human aging process. Also, it is safe and easily absorbed in the body. Hence the aim of this study was to examine the effectiveness and safety of a collagen and antioxidant-rich treatment compared to a placebo in relation to various skin and hair indicators in healthy adult human subjects. PATIENTS AND METHODS: Forty healthy adult non-pregnant/non-lactating women (aged 38-50 years) provided their informed consent in writing before their participation. Skin Radiance Collagen (SRC) treatment and a placebo were assessed for efficacy before application on Day 1, and post-application on Days 28 and 56, to measure changes in skin elasticity, hydration, brightness, pigmentation; texture, wrinkles, dryness, smoothness, fine lines, changes in the crow's feet region; as well as hair strength and hair fall. RESULTS: It was observed after 56 days that therapy with SRC, compared to placebo, produced a substantial effect on reduction of wrinkle depth and fine lines by 48.11% and 39%, respectively, with p-value <0.01 in the test group. There was a 15.69% improvement in skin hydration observed and 28% reduction in hair fall with p-value <0.01. CONCLUSION: SRC, a combination of collagen with hyaluronic acid (HA), biotin, and vitamins C and E, showed a significant improvement in skin and hair health, including improvements in skin elasticity, skin hydration, reduction in crow's feet area wrinkles and fine lines, hair fall, and decrease in roughness, leading to improved skin texture. Vitamin C in the formulation also acts as a collagen builder for the body and helps in preventing oxidative stress in the body. The test treatment SRC was found to be efficacious and safe in healthy human adult subjects. © 2024 Trehan et al. DOI: 10.2147/CCID.S438642 PMCID: PMC10942009 PMID: 38495912 Conflict of interest statement: The authors affirm that no associations have influenced the work reported in this paper. The authors report no conflicts of interest in this work.

Effects of biotin and coated cobalamin on lactation performance, nutrient digestion and rumen fermentation in Holstein dairy cows.

7. J Anim Physiol Anim Nutr (Berl). 2024 May;108(3):635-645. doi: 10.1111/jpn.13920. Epub 2024 Jan 10. Effects of biotin and coated cobalamin on lactation performance, nutrient digestion and rumen fermentation in Holstein dairy cows. Wang C(1), An J(1), Bu L(1), Liu Y(1), Liu Q(1), Guo G(1), Zhang J(1), Zhang Y(1). Author information: (1)Department of Animal Nutrition and Feed Science, College of Animal Sciences, Shanxi Agricultural University, Taigu, Shanxi, China. Biotin (BI) and cobalamin (CA) are essential for rumen propionate production and hepatic gluconeogenesis. The study evaluated the influence of BI or/and coated CA (CCA) on milk performance and nutrient digestion in cows. Sixty Holstein dairy cows were assigned in a 2 × 2 factorial arrangement and randomised block design to four groups. The factors were BI at 0 or 20 mg/day and CCA at 0 or 9 mg CA/day. Dry matter intake increased with BI addition but was unchanged with CCA supply. Addition of BI or CCA increased fat-corrected milk, milk fat and milk protein yields and feed efficiency. Moreover, lactose yield was increased by CCA addition. Dry matter, organic matter, crude protein and acid detergent fibre total-tract digestibility increased for BI or CCA supply. When CCA was supplemented, positive response of neutral detergent fibre digestibility to BI addition was enhanced. Supplementing BI did not affect pH, propionate content and acetate to propionate ratio, but increased total volatile fatty acids (VFA) and acetate contents. Supplementing CCA decreased pH and acetate to propionate ratio, but increased total VFA, acetate and propionate contents. Rumen protease and carboxymethyl-cellulase activities and fungi, bacteria and Butyrivibrio fibrisolvens numbers increased for BI or CCA supply. In addition, protozoa increased for BI addition, and protease activity and Prevotella ruminicola increased for CCA supply. When CCA was supplemented, positive responses of R. albus and Ruminobacter amylophilus numbers to BI addition were enhanced. Blood glucose concentration was unchanged with BI supply, but increased for CCA supply. Blood nonesterified fatty acids and β-hydroxybutyrate contents reduced with BI or CCA supply. Supplementation with BI or CCA increased blood BI or CA content. The results showed that supplementing BI or/and CCA improved lactation performance and nutrient digestion, and CCA supply did not enhance the lactation performance response to BI supply. © 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd. DOI: 10.1111/jpn.13920 PMID: 38197588 [Indexed for MEDLINE]

The effect of multivitamins on anxiety and depression in patients undergoing methadone maintenance treatment: A double-blind randomized controlled trial.

8. Int J Psychiatry Med. 2023 Nov;58(6):576-590. doi: 10.1177/00912174231179320. Epub 2023 May 31. The effect of multivitamins on anxiety and depression in patients undergoing methadone maintenance treatment: A double-blind randomized controlled trial. Lagzi N(1), Bateni A(1), Goli R(2), Talebiazar N(3). Author information: (1)Department of Community Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. (2)Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia, Iran. (3)Psychiatrist, Urmia University of Medical Sciences, Urmia, Iran. BACKGROUND: The prevalence of addiction is increasing in the world. Methadone Maintenance Treatment (MMT) can be associated with severe stress and mild to moderate depressive symptoms. Vitamins and minerals are commonly found in multivitamins seem to improve mood. Therefore, the aim of this study was to evaluate the effect of multivitamins on anxiety and depression in patients undergoing MMT in a double-blind randomized controlled trial. METHODS: The study was designed as a double-blind, randomized controlled trial and involved 70 male MMT patients over the age of 18. Participants were randomized to one of two groups, either those receiving multivitamins or those receiving a placebo for 12 weeks. The multivitamin capsule included vitamin E, B1, B2, B3, B5, B6, B12, C, biotin, folic acid, and zinc. Anxiety and depression were measured using standard questionnaires, before and after the intervention. RESULTS: The between-group comparison (i.e., intervention vs. placebo) indicated there was no significant difference in anxiety scores; however, there was a significant between-group difference in depression scores, favoring the intervention group. CONCLUSIONS: Multivitamin supplementation improved depression but did not have a significant impact on anxiety in patients undergoing MMT. DOI: 10.1177/00912174231179320 PMID: 37256965 [Indexed for MEDLINE] Conflict of interest statement: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Effect of biotin supplementation in infant formula: A multi-center study in Japan.

9. Pediatr Int. 2023 Jan;65(1):e15359. doi: 10.1111/ped.15359. Effect of biotin supplementation in infant formula: A multi-center study in Japan. Takahashi N(1), Shoji H(2), Arai H(3), Tanaka K(4), Kakiuchi S(5), Yoda H(3), Shimizu T(2). Author information: (1)Department of Pediatric and Neonatal Intensive Care, The University of Tokyo Hospital, Tokyo, Japan. (2)Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan. (3)Department of Neonatology, Toho University Omori Medical Center, Tokyo, Japan. (4)Division of Consultation liaison Department of Psychosocial Medicine, National Center for Child Health and Development, Tokyo, Japan. (5)Department of Pediatrics, The University of Tokyo, Tokyo, Japan. BACKGROUND: This non-randomized intervention study aimed to evaluate the effect of supplementing infant formula with biotin on biotin metabolism and on development. METHODS: We enrolled healthy Japanese infants (n = 84) and assigned them to groups offered Formula A (total biotin, 0.5 μg/100 kcal) or Formula B (total biotin, 2.4 μg/100 kcal) until they were 6 months of age, and completed an additional follow up to age 36 months. Urinary biotin concentrations were measured at 1 and 6 months, and were compared among breast-fed, Formula A-fed, and Formula B-fed infants at each age. In a follow-up subgroup analysis, we compared scores on the Ages and Stages Questionnaire, version 3 (ASQ-3), from 9 to 36 months among infants continuously fed Formula A, Formula B, or breastmilk. RESULTS: No adverse events occurred during the intervention period. At 1 month, urinary biotin concentrations were highest in Formula B-fed infants and lowest in Formula A-fed infants. At 6 months, Formula B-fed infants retained higher biotin levels than Formula A-fed and breast-fed infants. Both differences were statistically significant (P < 0.05). The breast-fed, Formula A-fed, and Formula B-fed groups had similar ASQ scores at 9-36 months. CONCLUSIONS: Biotin supplementation of infant formula contributed to improving biotin status in formula-fed infants. The results support the official approval of the use of biotin in infant formula by the government of Japan in 2014. © 2022 Japan Pediatric Society. DOI: 10.1111/ped.15359 PMID: 36680523 [Indexed for MEDLINE]

PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression-A Randomized Controlled Trial.

10. Nutrients. 2020 Nov 8;12(11):3422. doi: 10.3390/nu12113422. PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression-A Randomized Controlled Trial. Reininghaus EZ(1), Platzer M(1), Kohlhammer-Dohr A(1), Hamm C(1), Mörkl S(1), Bengesser SA(1), Fellendorf FT(1), Lahousen-Luxenberger T(1), Leitner-Afschar B(1), Schöggl H(1), Amberger-Otti D(1), Wurm W(1), Queissner R(1), Birner A(1), Falzberger VS(1), Painold A(1), Fitz W(1), Wagner-Skacel J(2), Brunnmayr M(3), Rieger A(1), Maget A(1), Unterweger R(1), Schwalsberger K(1), Reininghaus B(3), Lenger M(1), Bastiaanssen TFS(4)(5), Dalkner N(1). Author information: (1)Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, 8036 Graz, Austria. (2)Department of Medical Psychology and Psychosomatics, Medical University of Graz, 8036 Graz, Austria. (3)TZ-Justus Park, 4540 Bad Hall, Austria. (4)Department of Anatomy and Neuroscience, University College Cork, T12 YN60 Cork, Ireland. (5)APC Microbiome Ireland, University College Cork, T12 YN60 Cork, Ireland. Gut microbiota are suspected to affect brain functions and behavior as well as lowering inflammation status. Therefore, an effect on depression has already been suggested by recent research. The aim of this randomized double-blind controlled trial was to evaluate the effect of probiotic treatment in depressed individuals. Within inpatient care, 82 currently depressed individuals were randomly assigned to either receive a multistrain probiotic plus biotin treatment or biotin plus placebo for 28 days. Clinical symptoms as well as gut microbiome were analyzed at the begin of the study, after one and after four weeks. After 16S rRNA analysis, microbiome samples were bioinformatically explored using QIIME, SPSS, R and Piphillin. Both groups improved significantly regarding psychiatric symptoms. Ruminococcus gauvreauii and Coprococcus 3 were more abundant and β-diversity was higher in the probiotics group after 28 days. KEGG-analysis showed elevated inflammation-regulatory and metabolic pathways in the intervention group. The elevated abundance of potentially beneficial bacteria after probiotic treatment allows speculations on the functionality of probiotic treatment in depressed individuals. Furthermore, the finding of upregulated vitamin B6 and B7 synthesis underlines the connection between the quality of diet, gut microbiota and mental health through the regulation of metabolic functions, anti-inflammatory and anti-apoptotic properties. Concluding, four-week probiotic plus biotin supplementation, in inpatient individuals with a major depressive disorder diagnosis, showed an overall beneficial effect of clinical treatment. However, probiotic intervention compared to placebo only differed in microbial diversity profile, not in clinical outcome measures. DOI: 10.3390/nu12113422 PMCID: PMC7695208 PMID: 33171595 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.

Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial.

11. Trials. 2020 Jul 6;21(1):614. doi: 10.1186/s13063-020-04547-0. Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial. Beigmohammadi MT(1), Bitarafan S(2), Hoseindokht A(1), Abdollahi A(3)(4), Amoozadeh L(1), Mahmoodi Ali Abadi M(5), Foroumandi M(1). Author information: (1)Anaesthesiology and Intensive Care Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. (2)Iranian Center of Neurological Research (ICNR), Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, 1419733141, Iran. bitarafans@gmail.com. (3)Department of Pathology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. (4)Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. (5)Department of Laboratory, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. OBJECTIVES: This study will evaluate the main hypothesis that supplementation with vitamins A, B, C, D, and E significantly improves the severity and mortality rate in ICU patients with COVID-19. TRIAL DESIGN: This study is a randomized, single-blinded, two-arm (1:1 ratio) parallel group clinical trial. PARTICIPANTS: We are conducting this study in patients with COVID-19 admitted to intensive care units at the Imam Khomeini Hospital Complex in Tehran, Iran. The inclusion criteria are as follows: (1) aged between 20 and 60 years, (2) both male and female patients with COVID-19, (3) clinical or definitive diagnosis (using polymerase chain reaction (PCR) test), (4) patients have not participated in other clinical trials, and (5) no renal or hepatic abnormalities. The exclusion criteria are as follows: (1) patients with specific and rare viral diseases such as HIV and (2) patients who have been undergoing chemotherapy for the past month. INTERVENTION AND COMPARATOR: Duration of intervention: 7 days from randomization Intervention in the treatment group: Vitamin A 25,000 IU daily Vitamin D 600,000 IU once during study Vitamin E 300 IU twice daily Vitamin C is taken four times per day B vitamins are taken as a daily Soluvit [which included thiamine nitrate 3.1 mg, sodium riboflavin phosphate 4.9 mg (corresponding to vitamin B2 3.6 mg), nicotinamide 40 mg, pyridoxine hydrochloride 4.9 mg (corresponding to vitamin B6 4.0 mg), sodium pantothenate 16.5 mg (corresponding to pantothenic acid 15 mg), sodium ascorbate 113 mg (corresponding to vitamin C 100 mg), biotin 60 μg, folic acid 400 μg, and cyanocobalamin 5 μg] The control group will not receive any supplements or placebo. All supplements are made in Iran except for Soluvit (from Fresenius Kabi, New Zealand). MAIN OUTCOMES: 1. Weight, height, and BMI 2. Severity of pulmonary involvement according to CT scan 3. Respiratory support (invasive or non-invasive) 4. Percentage of oxygen saturation (SpO2 level) 5. Serum levels of WBC, CRP, ESR, IL6, IFN-G, and TNF-α 6. The patient's body temperature 7. The presence or absence of involvement of organs other than the lungs (e.g., heart, liver, kidneys) 8. Duration of hospitalization 9. Mortality rate RANDOMIZATION: At baseline, eligible patients were randomly assigned to a 1:1 ratio to one of two groups: intervention and control. Block randomization is used based on the gender of patients. BLINDING (MASKING): Patients are unaware of being placed in the intervention or control groups after signing consent. All treatment staff will be aware of which group each of the patients is in due to the specific conditions of the ICU and the absence of placebo for the control group. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The researchers plan to include 60 patients in total, with 30 patients in each group. TRIAL STATUS: This is the first version of the protocol which started on April 2, 2020. Recruitment began April 2, 2020, and is expected to be complete by July 4, 2020. TRIAL REGISTRATION: The Iranian Registry of Clinical Trials IRCT20200319046819N1 . Registered on April 4, 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol (Fig. 1, Table 1). DOI: 10.1186/s13063-020-04547-0 PMCID: PMC7336105 PMID: 32631405 [Indexed for MEDLINE] Conflict of interest statement: The authors declare that there are no competing interests in the present study.

Dietary interventions for multiple sclerosis-related outcomes.

12. Cochrane Database Syst Rev. 2020 May 19;5(5):CD004192. doi: 10.1002/14651858.CD004192.pub4. Dietary interventions for multiple sclerosis-related outcomes. Parks NE(1), Jackson-Tarlton CS(1), Vacchi L(2), Merdad R(3), Johnston BC(4). Author information: (1)Department of Medicine, Division of Neurology, Dalhousie University, Halifax, Canada. (2)Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy. (3)Department of Community Health and Epidemiology, Dalhousie University, Halifax, Canada. (4)Department of Nutrition, Texas A&M University, College Station, Texas, USA. Comment in Explore (NY). 2022 Mar-Apr;18(2):252-253. doi: 10.1016/j.explore.2021.12.007. Update of Cochrane Database Syst Rev. 2012 Dec 12;12:CD004192. doi: 10.1002/14651858.CD004192.pub3. BACKGROUND: Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease-modifying therapy appears to modulate the immune system to improve MS-related outcomes. There is substantial interest in the ability of dietary interventions to influence MS-related outcomes. This is an update of the Cochrane Review 'Dietary interventions for multiple sclerosis' (Farinotti 2003; Farinotti 2007; Farinotti 2012). OBJECTIVES: To assess the effects of dietary interventions (including dietary plans with recommendations for specific whole foods, macronutrients, and natural health products) compared to placebo or another intervention on health outcomes (including MS-related outcomes and serious adverse events) in people with MS. SEARCH METHODS: On 30 May 2019, we searched CENTRAL, MEDLINE, Embase, and Web of Science. We also searched ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform (ICTRP), and Networked Digital Library of Theses and Dissertations (NDLTD). We checked reference lists in identified trials and requested information from trial authors to identify any additional published or unpublished data. SELECTION CRITERIA: We included any randomized controlled trial (RCT) or controlled clinical trial (CCT) examining the effect of a dietary intervention versus placebo or another intervention among participants with MS on MS-related outcomes, including relapses, disability progression, and magnetic resonance imaging (MRI) measures. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. Planned primary outcomes were number of participants experiencing relapse and change in disability progression, according to a validated disability scale at the last reported follow-up. Secondary outcomes included MRI activity, safety, and patient-reported outcomes. We entered and analysed data in Review Manager 5. MAIN RESULTS: We found 41 full-text articles examining 30 trials following full-text review. Participants were adults with MS, defined by established criteria, presenting to MS clinics in Europe, North America, and the Middle East. Study design varied considerably, although all trials had at least one methodological issue leading to unknown or high risk of bias. Trials examined: supplementation to increase polyunsaturated fatty acids (PUFAs) (11 trials); a variety of antioxidant supplements (10 trials); dietary programmes (3 trials); and other dietary supplements (e.g. acetyl L-carnitine, biotin, creatine, palmitoylethanolamide, probiotic, riboflavin) (6 trials). In three trials comparing PUFAs with monounsaturated fatty acids (MUFAs), the evidence was very uncertain concerning difference in relapses (risk ratio (RR) 1.02, 95% confidence interval (CI) 0.88 to 1.20; 3 studies, 217 participants; 75% in the PUFA group versus 74% in the MUFA group; very low-certainty evidence). Among four trials comparing PUFAs with MUFAs, there may be little to no difference in global impression of deterioration (RR 0.85, 95% CI 0.71 to 1.03; 4 studies, 542 participants; 40% in the PUFA group versus 47% in the MUFA group; low-certainty evidence). In two trials comparing PUFAs with MUFAs (102 participants), there was very low-certainty evidence for change in disability progression. None of the PUFA versus MUFA trials examined MRI outcomes. In one trial comparing PUFAs with MUFAs (40 participants), there were no serious adverse events; based on low-certainty evidence. In two trials comparing different PUFAs (omega-3 versus omega-6), there may be little to no difference in relapses (RR 1.02, 95% CI 0.62 to 1.66; 2 studies, 129 participants; 30% in the omega-3 versus 29% in the omega-6 group; low-certainty evidence). Among three trials comparing omega-3 with omega-6, there may be little to no difference in change in disability progression, measured as mean change in Expanded Disability Status Scale (EDSS) (mean difference (MD) 0.00, 95% CI -0.30 to 0.30; 3 studies, 166 participants; low-certainty evidence). In one trial comparing omega-3 with omega-6, there was likely no difference in global impression of deterioration (RR 0.99, 95% CI 0.51 to 1.91; 1 study, 86 participants; 29% in omega-3 versus 29% in omega-6 group; moderate-certainty evidence). In one trial comparing omega-3 with omega-6 (86 participants), there was likely no difference in number of new T1- weighted gadolinium-enhancing lesions, based on moderate-certainty evidence. In four trials comparing omega-3 with omega-6, there may be little to no difference in serious adverse events (RR 1.12, 95% CI 0.38 to 3.31; 4 studies, 230 participants; 6% in omega-3 versus 5% in omega-6 group; low-certainty evidence). In four trials examining antioxidant supplementation with placebo, there may be little to no difference in relapses (RR 0.98, 95% CI 0.59 to 1.64; 4 studies, 345 participants; 17% in the antioxidant group versus 17% in the placebo group; low-certainty evidence). In six trials examining antioxidant supplementation with placebo, the evidence was very uncertain concerning change in disability progression, measured as mean change of EDSS (MD -0.19, 95% CI -0.49 to 0.11; 6 studies, 490 participants; very low-certainty evidence). In two trials examining antioxidant supplementation with placebo, there may be little to no difference in global impression of deterioration (RR 0.99, 95% 0.50 to 1.93; 2 studies, 190 participants; 15% in the antioxidant group versus 15% in the placebo group; low-certainty evidence). In two trials examining antioxidant supplementation with placebo, the evidence was very uncertain concerning difference in gadolinium-enhancing lesions (RR 0.67, 95% CI 0.09 to 4.88; 2 studies, 131 participants; 11% in the antioxidant group versus 16% in the placebo group; very low-certainty evidence). In three trials examining antioxidant supplementation versus placebo, there may be little to no difference in serious adverse events (RR. 0.72, 95% CI 0.17 to 3.08; 3 studies, 222 participants; 3% in the antioxidant group versus 4% in the placebo group; low-certainty evidence). AUTHORS' CONCLUSIONS: There are a variety of controlled trials addressing the effects of dietary interventions for MS with substantial variation in active treatment, comparator, and outcomes of interest. PUFA administration may not differ when compared to alternatives with regards to relapse rate, disability worsening, or overall clinical status in people with MS, but evidence is uncertain. Similarly, at present, there is insufficient evidence to determine whether supplementation with antioxidants or other dietary interventions have any impact on MS-related outcomes. Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. DOI: 10.1002/14651858.CD004192.pub4 PMCID: PMC7388136 PMID: 32428983 [Indexed for MEDLINE] Conflict of interest statement: Natalie E Parks has provided consulting services to Biogen, EMD Serono, Roche, and Sanofi Genzyme. She has accepted funds from Biogen and Roche for travel to a scientific conference. She has acted as site sub‐investigator for clinical trials for Biogen, MedDay, Sanofi Genzyme, and Roche. She is the recipient of a Killam Predoctoral Scholarship, Nova Scotia Graduate Scholarship, and Dalhousie Medical Research Foundation Multiple Sclerosis Graduate Studentship. Caitlin S Jackson‐Tarlton: nothing to declare
Laura Vacchi: nothing to declare
Roah Merdad: nothing to declare
Bradley C Johnston: As part of his recruitment to Texas A&M University, BCJ received a start‐up grant from Texas A&M AgriLife Research to fund investigator‐initiated research related to saturated and polyunsaturated fats. The grant was from Texas A&M AgriLife institutional funds from interest and investment earnings, not a sponsoring organization, industry, or company.

A Dermonutrient Containing Special Collagen Peptides Improves Skin Structure and Function: A Randomized, Placebo-Controlled, Triple-Blind Trial Using Confocal Laser Scanning Microscopy on the Cosmetic Effects and Tolerance of a Drinkable Collagen Supplement.

13. J Med Food. 2020 Feb;23(2):147-152. doi: 10.1089/jmf.2019.0197. A Dermonutrient Containing Special Collagen Peptides Improves Skin Structure and Function: A Randomized, Placebo-Controlled, Triple-Blind Trial Using Confocal Laser Scanning Microscopy on the Cosmetic Effects and Tolerance of a Drinkable Collagen Supplement. Laing S(1), Bielfeldt S(1), Ehrenberg C(1), Wilhelm KP(1). Author information: (1)proDERM Institute for Applied Dermatological Research, Schenefeld-Hamburg, Germany. The purpose of this randomized, placebo-controlled, triple-blind trial on 60 healthy female volunteers was to assess the cosmetic effects on skin quality of a food supplement containing special collagen peptides together with acerola extract, vitamin C, vitamin E, biotin, and zinc after an intake of 12 weeks (Elasten®, QUIRIS Healthcare, Germany). To reduce assessment bias maximally and increase the accuracy and objectivity of the outcomes, the trial design was triple blinded in a manner that neither the subjects nor the person administering the products nor the person who assessed the primary outcomes knew which subjects had received the test product and which had received the placebo. The expert grader assessing the confocal laser scanning microscopy images was additionally blinded regarding the time when the image was taken (on days 1 or 85). The objective, blinded, and validated image analyses using confocal laser scanning microscopy showed a significant improvement of the collagen structure of facial skin (primary endpoint) after intake of the test product, while no improvements were found after intake of the placebo. The proven positive nutritional effect on the collagen structure was fully consistent with positive subjective evaluations of relevant skin parameters such as elasticity, crinkliness/wrinkliness, and evenness in different body areas such as face, hands, décolleté, neck, backside, legs, and belly, all serving as secondary endpoints. The test product was found to be safe and very well tolerated. A cosmetically relevant improvement of the facial skin was demonstrated after administration of the collagen supplement. DOI: 10.1089/jmf.2019.0197 PMCID: PMC7041324 PMID: 32017646 [Indexed for MEDLINE] Conflict of interest statement: No competing financial interests exist.

A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study.

14. Nutrients. 2019 Oct 17;11(10):2494. doi: 10.3390/nu11102494. A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study. Bolke L(1), Schlippe G(2), Gerß J(3), Voss W(4). Author information: (1)Dermatest GmbH, Engelstraße 37, D-48143 Münster, Germany. dr.bolke@dermatest.de. (2)Dermatest GmbH, Engelstraße 37, D-48143 Münster, Germany. dr.schlippe@dermatest.de. (3)Institut für Biometrie und klinische Forschung (IBKF) der Westfälischen Wilhelms-Universität Münster, Schmedding Straße 56, D-48149 Münster, Germany. joachim.gerss@ukmuenster.de. (4)Dermatest GmbH, Engelstraße 37, D-48143 Münster, Germany. dr.voss@dermatest.de. The purpose of this randomized, placebo-controlled, blind study was to investigate the effects of the drinkable nutraceutical ELASTEN® (QUIRIS Healthcare, Gütersloh, Germany) on skin aging and skin health. Drinking ampoules provides a blend of 2.5 g of collagen peptides, acerola fruit extract, vitamin C, zinc, biotin, and a native vitamin E complex. This controlled interventional trial was performed on 72 healthy women aged 35 years or older. They received either the food supplement (n = 36) or a placebo (n = 36) for twelve weeks. A skin assessment was carried out and based on objective validated methods, including corneometry (skin hydration), cutometry (elasticity), the use of silicon skin replicas with optical 3D phase-shift rapid in-vivo measurements (PRIMOS) (roughness), and skin sonography (density). The verum group was followed for an additional four weeks (without intake of the test product) to evaluate the sustainability of the changes induced by the intake of the test product. The test product significantly improved skin hydration, elasticity, roughness, and density. The differences between the verum group and the placebo group were statistically significant for all test parameters. These positive effects were substantially retained during the follow-up. The measured effects were fully consistent with the subjective assessments of the study participants. The nutraceutical was well tolerated. DOI: 10.3390/nu11102494 PMCID: PMC6835901 PMID: 31627309 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest. The sponsor had no influence on execution, analysis and interpretation of the data.

Effect of biotin supplementation on milk yield of Girolando cows reared in a tropical climate.

15. Trop Anim Health Prod. 2019 Jul;51(6):1661-1665. doi: 10.1007/s11250-019-01862-w. Epub 2019 Mar 16. Effect of biotin supplementation on milk yield of Girolando cows reared in a tropical climate. Queiroz PJB(1), Silva DC(2), Borges PAC(2), Pedroso ACBR(2), Vinhal APA(2), Rabelo RE(3), Silva LAF(2). Author information: (1)Escola de Veterinária e Zootecnia, Universidade Federal de Goiás, Goiânia, GO, 74001-970, Brazil. paulojose.vet@hotmail.com. (2)Escola de Veterinária e Zootecnia, Universidade Federal de Goiás, Goiânia, GO, 74001-970, Brazil. (3)Universidade Federal de Jataí, Campus Jatobá, Jataí, GO, 75804-020, Brazil. The objective of this study was to evaluate the effect of biotin supplementation on milk yield and the reproductive efficiency in Girolando cows. The study was conducted on a dairy farm located in central Brazil, between April 2012 and December 2016. Thirty-six Girolando cows in their first lactation were used. The cows were distributed in two treatment groups, each with equivalent weight distributions. Control treatment (CT) cows (n = 18) received a diet without any supplemental biotin, whereas biotin treatment (BT) cows (n = 18) received a diet supplemented with 20 mg/day of biotin during lactation. Biotin supplementation caused a significant increase (p = 0.001) in milk yield in the second lactation, and a trend (p = 0.09) toward higher average production during the three lactations was evaluated. There was no statistically significant difference between the treatments in terms of reproductive efficiency. In conclusion, biotin supplementation (20 mg/day) during lactation for Girolando cows reared in a tropical climate is able to increase milk yield, but does not improve reproductive efficiency. DOI: 10.1007/s11250-019-01862-w PMID: 30879247 [Indexed for MEDLINE]